Unlike expensive positron emission tomography (PET) scans or invasive lumbar punctures, the new blood test measures the ratio ...

Nicotine, an addictive stimulant found in the tobacco plant, can increase the release of dopamine and other neurotransmitters ...

A stroke drug called GAI-17 protected mouse brains even six hours after damage began—and may one day help fight Alzheimer’s ...

Leqembi is the first FDA-approved drug shown to slow the progression of early-stage Alzheimer’s. Medi-Cal can cover Leqembi ...

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug. They ...

Scientists have used AI to re-analyse a clinical trial for an Alzheimer's medicine, and identified a group of patients who responded to treatment. The ...

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics ...

Stroke kills millions, but Osaka researchers have unveiled GAI-17, a drug that halts toxic GAPDH clumping, slashes brain ...

Eli Lilly and Company (NYSE: LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

Despite concerns raised by clinicians and ethicists, direct-to-consumer testing for Alzheimer’s disease biomarkers is here, ...